MBCI Stock Chart & Stats
<$0.01
>-$0.01(-33.33%)
At close: 4:00 PM EDT
<$0.01
>-$0.01(-33.33%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume1.00K
Average Volume (3M)N/A
Market Cap
$12.87K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-13.09
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding64,364,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MBCI FAQ
What was MabCure Inc.’s price range in the past 12 months?
MabCure Inc. lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
What is MabCure Inc.’s market cap?
MabCure Inc.’s market cap is $12.87K.
When is MabCure Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MabCure Inc.’s earnings last quarter?
Currently, no data Available
Is MabCure Inc. overvalued?
According to Wall Street analysts MabCure Inc.’s price is currently Overvalued.
Does MabCure Inc. pay dividends?
MabCure Inc. does not currently pay dividends.
What is MabCure Inc.’s EPS estimate?
MabCure Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MabCure Inc. have?
MabCure Inc. has 64,364,000 shares outstanding.
What happened to MabCure Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MabCure Inc.?
Currently, no hedge funds are holding shares in MBCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MabCure Inc.
MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan. MabCure Inc. was founded in 2006 and is based in White Plains, New York.
Ownership Overview
―
Insiders
―
Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors